Herantis Pharma Plc shares subscribed with option rights
Herantis Pharma Plc
Company release 28 May 2019 at 9:00am
32,000 new shares of Herantis Pharma Plc have been subscribed with option rights of the option programs 2010 and 2014. The new shares are expected to be registered into the Trade Register today on 28 May 2019, as of which date the new shares will establish shareholder rights.
The share capital will not increase with subscriptions. The entire aggregate subscription price for the new shares of EUR 1.60 will be entered in the invested unrestricted equity reserve of the company. As a result of the share subscriptions, the number of shares and votes of Herantis Pharma Plc will increase to 6,062,287 shares and votes.
Trading with the new shares is expected to commence on NASDAQ Helsinki Ltd’s First North Finland marketplace together with the existing shares on 31 May 2019.
Share information of the Herantis Pharma Plc share after the registration of the new shares:
Trading Code: HRTIS
ISIN code: FI4000087861
List: First North Helsinki
Industry: Health Care
Number of Shares: 6,062,287
Share Capital: 80,000.00 euro
Herantis Pharma Plc., Pekka Simula, CEO, telephone: +358 40 7300 445
Company web site: www.herantis.com
Certified Advisor: UB Securities Ltd, telephone: +358 9 25 380 225
About Herantis Pharma Plc
Herantis Pharma Plc is an innovative drug development company focused on regenerative medicine and unmet clinical needs. Our clinical stage assets CDNF and Lymfactin® are based on globally leading scientific research in their fields. They both aim at breakthrough in the treatment of severe diseases: CDNF in neurodegenerative diseases such as Parkinson’s disease; and Lymfactin® in breast cancer associated lymphedema with potential also in other lymphedemas. The shares of Herantis are listed on the First North Finland marketplace run by Nasdaq Helsinki stock exchange.